CagriSema trial registration describes switching type 2 diabetes participants off semaglutide
A ClinicalTrials.gov registration states that participants with type 2 diabetes already on once-weekly semaglutide will switch to once-weekly CagriSema for about six months, with all participants receiving the tested treatment.
2026 · Trial registration · n=210 · Human · Published October 4, 2026
This page reports what published studies found. It is not medical advice, no provider-patient relationship is created by reading it, and nothing here is a recommendation to use any compound. Talk with a licensed clinician about your own situation. Read the full disclaimer.
What the registration says
This is a trial registration describing a planned study in people: the record states that its purpose is to look at the safety and tolerability of switching from semaglutide to CagriSema in participants who have type 2 diabetes. The source excerpt provided here does not state how many human participants are planned, so no enrolment figure is reported on this page.
The registration states that all participants will get CagriSema, the treatment being tested, and that participants will be in the study for about 6 months. No results are reported, because this is a registration record rather than a published analysis.
How the arms are described
Three experimental arms are listed, all described as switches from once-weekly subcutaneous semaglutide. In the first, participants switch to once-weekly CagriSema dose 1. In the second, participants switch to once-weekly CagriSema dose 2, followed by dose 1. In the third, participants switch to once-weekly CagriSema dose 3, followed by dose 2 and dose 1.
The intervention section states only that CagriSema will be administered subcutaneously once weekly. The registration labels the doses as dose 1, dose 2 and dose 3 and does not state milligram amounts for any of them in this excerpt.
Reported dosing
The registration describes the schedule and route but not the quantity: participants with type 2 diabetes previously treated with once-weekly subcutaneous semaglutide are assigned to once-weekly subcutaneous CagriSema at dose 1, dose 2 then dose 1, or dose 3 then dose 2 then dose 1. Because the excerpt gives no numbers or units, no milligram regimen can be reported here.
Limitations
This is a registration, not a results publication, so nothing is known from it about outcomes, tolerability findings, or dropouts. All three listed arms are experimental and every participant receives CagriSema, so the record describes no placebo or active comparator group against which the switch could be measured.
The excerpt does not state the planned number of participants, the number of study sites, the countries involved, or the sponsor's role in analysis. Dose levels are given only as labels, and the stated duration of about 6 months limits what any eventual report could say about longer-term tolerability.
Regulatory context
Cagrilintide, including the coformulation with semaglutide known as CagriSema, is not an FDA-approved drug for any use. This status comes from the site's regulatory review, not from the registration described above.
Study-reported dosing
| Regimen as reported | Population | Route | Source |
|---|---|---|---|
| once-weekly CagriSema dose 1, administered subcutaneouslyThe registration labels this as dose 1 and does not state a milligram amount. | participants with type 2 diabetes previously treated with once-weekly subcutaneous semaglutide | Subcutaneous | Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema (2026) Trial registrationHumann=210 |
| once-weekly CagriSema dose 2, followed by dose 1, administered subcutaneouslyDose levels are given only as labels; no numbers or units appear in the excerpt. | participants with type 2 diabetes previously treated with once-weekly subcutaneous semaglutide | Subcutaneous | Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema (2026) Trial registrationHumann=210 |
| once-weekly CagriSema dose 3, followed by dose 2 and dose 1, administered subcutaneouslyDose levels are given only as labels; no numbers or units appear in the excerpt. | participants with type 2 diabetes previously treated with once-weekly subcutaneous semaglutide | Subcutaneous | Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema (2026) Trial registrationHumann=210 |
Claims and where they come from
Each statement below is followed by the passage of the source record it was checked against.
The registration states the study is intended to examine safety and tolerability of a switch from semaglutide to CagriSema in people with type 2 diabetes.
“The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes.”
Every participant is assigned to receive CagriSema, so the record describes no placebo or comparator arm.
“All participants will get CagriSema, the treatment being tested.”
The planned participation period is about six months.
“Participants will be in this clinical study for about 6 months.”
One arm has participants previously on once-weekly subcutaneous semaglutide switch directly to once-weekly CagriSema dose 1.
“Participants previously treated with once-weekly semaglutide subcutaneously (s.c.) will switch to once-weekly CagriSema dose 1.”
Another arm describes a stepped sequence from dose 3 down to dose 2 and then dose 1.
“will switch to once-weekly CagriSema dose 3, followed by dose 2 and dose 1.”
The intervention is described as subcutaneous and once weekly, without stated milligram amounts.
“CagriSema: CagriSema will be administered s.c. once weekly.”
Common questions
Was there a control group?
No comparator is described. The registration states that all participants will get CagriSema, the treatment being tested, and all three listed arms are labelled experimental.
Does the registration say how much CagriSema is given?
No. It states that CagriSema will be administered subcutaneously once weekly and refers to dose 1, dose 2 and dose 3 without stating milligram amounts in this excerpt.
Are there any results?
No. This is a registration record describing a planned study, and the excerpt reports no outcomes, safety findings, or participant numbers.
How long are participants involved?
The registration states that participants will be in the clinical study for about 6 months.
Source
- 1.Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema (2026)Trial registrationhumann=210NCT NCT07817251